{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:06:29Z","timestamp":1788926789421,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03341-3","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:07:38Z","timestamp":1784714858000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nano drug delivery of a new scfv-based immunotoxin by chitosan nanoparticles upgrades its efficiency against breast cancer"],"prefix":"10.1007","volume":"43","author":[{"given":"Ehsan","family":"Rezaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamideh","family":"Mahmoodzadeh Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jafar","family":"Amani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"issue":"3","key":"3341_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrc1295","volume":"4","author":"F Michor","year":"2004","unstructured":"Michor F, Iwasa Y, Nowak MA. Dynamics of cancer progression. Nat Rev Cancer. 2004;4(3):197\u2013205.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"3341_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3322\/caac.20073","volume":"60","author":"A Jemal","year":"2010","unstructured":"Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. Cancer J Clin. 2010;60(5):277\u2013300.","journal-title":"Cancer J Clin"},{"issue":"11","key":"3341_CR3","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.7150\/ijbs.21635","volume":"13","author":"Y-S Sun","year":"2017","unstructured":"Sun Y-S, Zhao Z, Yang Z-N, Xu F, Lu H-J, Zhu Z-Y, et al. Risk Factors and Preventions of Breast Cancer. Int J Biol Sci. 2017;13(11):1387\u201397.","journal-title":"Int J Biol Sci"},{"key":"3341_CR4","doi-asserted-by":"publisher","first-page":"172912","DOI":"10.1016\/j.ejphar.2020.172912","volume":"870","author":"E Rezaie","year":"2020","unstructured":"Rezaie E, Amani J, Pour AB, Hosseini HM. A new scfv-based recombinant immunotoxin against EPHA2-overexpressing breast cancer cells; High in vitro anti-cancer potency. Eur J Pharmacol. 2020;870:172912.","journal-title":"Eur J Pharmacol"},{"key":"3341_CR5","doi-asserted-by":"crossref","unstructured":"Heiat M, Yeganeh HH, Alavian SM, Rezaie E. Immunotoxins immunotherapy against hepatocellular carcinoma: A promising prospect. Toxins. 2021;13(10):719.","DOI":"10.3390\/toxins13100719"},{"issue":"20","key":"3341_CR6","doi-asserted-by":"publisher","first-page":"9514","DOI":"10.1073\/pnas.91.20.9514","volume":"91","author":"CB Siegall","year":"1994","unstructured":"Siegall CB, Liggitt D, Chace D, Tepper MA, Fell HP. Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity. Proc Natl Acad Sci. 1994;91(20):9514\u20138.","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"3341_CR7","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s10528-021-10163-7","volume":"60","author":"S Parvin","year":"2022","unstructured":"Parvin S, Sedighian H, Sohrabi E, Mahboobi M, Rezaei M, Ghasemi D, et al. Prediction of Genes Involved in Lung Cancer with a Systems Biology Approach Based on Comprehensive Gene Information. Biochem Genet. 2022;60(4):1253\u201373.","journal-title":"Biochem Genet"},{"key":"3341_CR8","doi-asserted-by":"crossref","unstructured":"Keshtvarz M, Mahboobi M, Kieliszek M, Miecznikowski A, Sedighian H, Rezaei M et al. Engineering of cytolethal distending toxin b by its reducing immunogenicity and maintaining stability as a new drug candidate for tumor therapy; an in silico study. Toxins. 2021;13(11):785.","DOI":"10.3390\/toxins13110785"},{"issue":"4\u20135","key":"3341_CR9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10930-022-10074-5","volume":"41","author":"H Hashemi Yeganeh","year":"2022","unstructured":"Hashemi Yeganeh H, Heiat M, Alavian SM, Rezaei E. A New Combination: Anti Glypican-3 scFv and Diphtheria Toxin with the Best Flexible Linker. Protein J. 2022;41(4\u20135):527\u201342.","journal-title":"Protein J"},{"issue":"6","key":"3341_CR10","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1080\/07391102.2020.1841025","volume":"40","author":"M Mohammadi","year":"2022","unstructured":"Mohammadi M, Rezaie E, Sakhteman A, Zarei N. A highly potential cleavable linker for tumor targeting antibody-chemokines. J Biomol Struct Dynamics. 2022;40(6):2546\u201356.","journal-title":"J Biomol Struct Dynamics"},{"key":"3341_CR11","doi-asserted-by":"crossref","unstructured":"Yeganeh HH, Heiat M, Kieliszek M, Alavian SM, Rezaie E. DT389-YP7, a recombinant immunotoxin against glypican-3 that inhibits hepatocellular cancer cells: An in vitro study. Toxins. 2021;13(11):749.","DOI":"10.3390\/toxins13110749"},{"issue":"4","key":"3341_CR12","doi-asserted-by":"publisher","first-page":"428","DOI":"10.4103\/1735-5362.350243","volume":"17","author":"M Ataee","year":"2022","unstructured":"Ataee M, Mirhosseini S, Mirnejad R, Rezaie E, Hosseini H, Amani J. Design of two immunotoxins based rovalpituzumab antibody against DLL3 receptor; A promising potential opportunity. Res Pharm Sci. 2022;17(4):428\u201344.","journal-title":"Res Pharm Sci"},{"key":"3341_CR13","doi-asserted-by":"crossref","unstructured":"Keshtvarz M, Rezaei E, Amani J, Pourmand MR, Salimian J, Sarial S et al. A novel shiga based immunotoxin against Fn-14 receptor on colorectal and lung cancer. Int Immunopharmacol. 2022;110:109076.","DOI":"10.1016\/j.intimp.2022.109076"},{"issue":"6","key":"3341_CR14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2174\/156800908785699315","volume":"8","author":"PW Janes","year":"2008","unstructured":"Janes PW, Adikari S, Lackmann M. Eph\/ephrin signalling and function in oncogenesis: lessons from embryonic development. Curr Cancer Drug Targets. 2008;8(6):473\u201389.","journal-title":"Curr Cancer Drug Targets"},{"issue":"12","key":"3341_CR15","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1002\/dvdy.20978","volume":"235","author":"H Kouros-Mehr","year":"2006","unstructured":"Kouros-Mehr H, Werb Z. Candidate regulators of mammary branching morphogenesis identified by genome\u2010wide transcript analysis. Dev dynamics: official publication Am Association Anatomists. 2006;235(12):3404\u201312.","journal-title":"Dev dynamics: official publication Am Association Anatomists"},{"issue":"16suppl","key":"3341_CR16","doi-asserted-by":"publisher","first-page":"9583","DOI":"10.1200\/jco.2005.23.16_suppl.9583","volume":"23","author":"M Pan","year":"2005","unstructured":"Pan M. Overexpression of EphA2 gene in invasive human breast cancer and its association with hormone receptor status. J Clin Oncol. 2005;23(16suppl):9583.","journal-title":"J Clin Oncol"},{"issue":"12","key":"3341_CR17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S0167-7799(98)01226-8","volume":"16","author":"Y Reiter","year":"1998","unstructured":"Reiter Y, Pastan I. Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Trends Biotechnol. 1998;16(12):513\u201320.","journal-title":"Trends Biotechnol"},{"issue":"3","key":"3341_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jconrel.2008.03.010","volume":"128","author":"H Chen","year":"2008","unstructured":"Chen H, Gao J, Lu Y, Kou G, Zhang H, Fan L, et al. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy. J Controlled Release. 2008;128(3):209\u201316.","journal-title":"J Controlled Release"},{"issue":"2","key":"3341_CR19","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s10989-019-09901-8","volume":"26","author":"E Rezaie","year":"2020","unstructured":"Rezaie E, Pour AB, Amani J, Hosseini HM. Bioinformatics predictions, expression, purification and structural analysis of the PE38KDEL-scfv immunotoxin against EPHA2 receptor. Int J Pept Res Ther. 2020;26(2):979\u201396.","journal-title":"Int J Pept Res Ther"},{"issue":"1","key":"3341_CR20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.colsurfb.2007.04.009","volume":"59","author":"Q Gan","year":"2007","unstructured":"Gan Q, Wang T. Chitosan nanoparticle as protein delivery carrier\u2014systematic examination of fabrication conditions for efficient loading and release. Colloids Surf B. 2007;59(1):24\u201334.","journal-title":"Colloids Surf B"},{"issue":"5","key":"3341_CR21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1179\/016164107X165282","volume":"29","author":"AM Stark","year":"2007","unstructured":"Stark AM, Hugo H-H, Tscheslog H, Mehdorn HM. p53, BCL-2 and BAX in non-small cell lung cancer brain metastases: a comparison of real-time RT-PCR, ELISA and immunohistochemical techniques. Neurol Res. 2007;29(5):435\u201340.","journal-title":"Neurol Res"},{"issue":"7","key":"3341_CR22","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/cdd.2013.12","volume":"20","author":"M Farhang Ghahremani","year":"2013","unstructured":"Farhang Ghahremani M, Goossens S, Nittner D, Bisteau X, Bartunkova S, Zwolinska A, et al. p53 promotes VEGF expression and angiogenesis in the absence of an intact p21-Rb pathway. Cell Death Differ. 2013;20(7):888\u201397.","journal-title":"Cell Death Differ"},{"issue":"3","key":"3341_CR23","first-page":"156","volume":"5","author":"A Ghadi","year":"2014","unstructured":"Ghadi A, Mahjoub S, Tabandeh F, Talebnia F. Synthesis and optimization of chitosan nanoparticles: Potential applications in nanomedicine and biomedical engineering. Caspian J Intern Med. 2014;5(3):156\u201361.","journal-title":"Caspian J Intern Med"},{"issue":"2","key":"3341_CR24","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/app.25920","volume":"105","author":"PZ Hong","year":"2007","unstructured":"Hong PZ, Li SD, Ou CY, Li CP, Yang L, Zhang CH. Thermogravimetric analysis of chitosan. J Appl Polym Sci. 2007;105(2):547\u201351.","journal-title":"J Appl Polym Sci"},{"key":"3341_CR25","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.2147\/IJN.S129300","volume":"12","author":"B-JL Van Hong Nguyen","year":"2017","unstructured":"Van Hong Nguyen B-JL. Protein corona: a new approach for nanomedicine design. Int J Nanomed. 2017;12:3137.","journal-title":"Int J Nanomed"},{"issue":"1","key":"3341_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2217\/nnm.15.188","volume":"11","author":"C Corbo","year":"2016","unstructured":"Corbo C, Molinaro R, Parodi A, Toledano Furman NE, Salvatore F, Tasciotti E. The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery. Nanomedicine. 2016;11(1):81\u2013100.","journal-title":"Nanomedicine"},{"issue":"1","key":"3341_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jconrel.2004.08.010","volume":"100","author":"SA Agnihotri","year":"2004","unstructured":"Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro-and nanoparticles in drug delivery. J Controlled Release. 2004;100(1):5\u201328.","journal-title":"J Controlled Release"},{"issue":"7","key":"3341_CR28","first-page":"1837","volume":"9","author":"IA Sogias","year":"2008","unstructured":"Sogias IA, Williams AC, Khutoryanskiy VV. Why is chitosan mucoadhesive? Biomacromolecules. 2008;9(7):1837\u201342.","journal-title":"Why is chitosan mucoadhesive? Biomacromolecules"},{"issue":"1","key":"3341_CR29","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.addr.2009.08.004","volume":"62","author":"S Mao","year":"2010","unstructured":"Mao S, Sun W, Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev. 2010;62(1):12\u201327.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"3341_CR30","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s11030-015-9616-0","volume":"19","author":"M Mohammadi-Khanaposhtani","year":"2015","unstructured":"Mohammadi-Khanaposhtani M, Safavi M, Sabourian R, Mahdavi M, Pordeli M, Saeedi M, et al. Design, synthesis, in vitro cytotoxic activity evaluation, and apoptosis-induction study of new 9 (10 H)-acridinone-1, 2, 3-triazoles. Mol Diversity. 2015;19(4):787\u201395.","journal-title":"Mol Diversity"},{"key":"3341_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.dnarep.2016.04.008","volume":"42","author":"A Karimian","year":"2016","unstructured":"Karimian A, Ahmadi Y, Yousefi B. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair. 2016;42:63\u201371.","journal-title":"DNA Repair"},{"issue":"9","key":"3341_CR32","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1093\/emboj\/18.9.2330","volume":"18","author":"A Nechushtan","year":"1999","unstructured":"Nechushtan A, Smith CL, Hsu YT, Youle RJ. Conformation of the Bax C-terminus regulates subcellular location and cell death. EMBO J. 1999;18(9):2330\u201341.","journal-title":"EMBO J"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03341-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03341-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03341-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:21:22Z","timestamp":1788924082000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03341-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["3341"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03341-3","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All evaluations were carried out following ethical standards and oversight by the University\u2019s Ethics Committee (Ethic Number IR.BMSU.REC.1398.410).","order":4,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"230"}}